Drug intelligence / Profile preview

IMB-106

Development stage: Preclinical
Lead developer: IM Biologics
Modality: Recombinant Proteins and Enzymes

Overview

IMB-106 is a preclinical drug candidate developed by IM Biologics for the treatment of various autoimmune diseases. It is engineered using the proprietary IM-OpDECon (Optimized Dual-Effector Control) technology, which represents a next-generation modality designed to provide enhanced therapeutic control by modulating dual immune effectors. The specific molecular targets of IMB-106 have not been disclosed by the developer. Currently, the program is in the lead optimization phase of development.

Targets

TNFSF4 (Tumor necrosis factor ligand superfamily member 4)

Beyond the preview

Go deeper on IMB-106.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMB-106.

Explore the full profile